AZTherapies

AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.

AZTherapies, Inc. is a privately held advanced clinical stage pharmaceutical company developing breakthrough treatments for multiple neurodegeneration and neuroinflammation-related CNS diseases, including Alzheimer’s (AD), ischemic stroke and ALS. Built around a broad IP portfolio exclusively licensed from Harvard Medical School and Massachusetts General Hospital, AZTherapies’ initial product (ALZT-OP1) is a novel multi-action combination drug regimen to modify disease progression by slowing down or halting Alzheimer’s disease early in its development. The ALZT-OP1 program is currently enrolling patients in a Phase III study under a Special Protocol Assessment with the FDA.